1
|
Sidrônio MGS, Castelo Branco APOT, Abbadi BL, Macchi F, Silveira MD, Lock GDA, Costa TD, de Araújo DM, Cibulski S, Bizarro CV, Machado P, Basso LA, Rodrigues-Junior VS. Effects of tafenoquine against active, dormant and resistant Mycobacterium tuberculosis. Tuberculosis (Edinb) 2021; 128:102089. [PMID: 34004588 DOI: 10.1016/j.tube.2021.102089] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 05/07/2021] [Accepted: 05/09/2021] [Indexed: 10/21/2022]
Abstract
Antimalarial drugs have been suggested as promising scaffolds with anti-tubercular activities. In this work, we demonstrated, for the first time, the effectiveness of tafenoquine against mycobacteria. Firstly, tafenoquine inhibited the growth of Mycobacterium smegmatis and Mycobacterium tuberculosis with lower MICs values as compared to other antimalarial drugs, such as mefloquine, chloroquine, and primaquine. Importantly, tafenoquine was active against three multi-drug resistant strains of M. tuberculosis with MIC values similar to pan-sensitive strains, suggesting that tafenoquine is capable of evading the major mechanisms of resistance found in drug-resistant clinical isolates of M. tuberculosis. Importantly, tafenoquine displayed a synergistic effect when combined with mefloquine. In addition, tafenoquine displayed an improved activity compared to the groups treated with both isoniazid and rifampicin in the six-week nutrient starved M. tuberculosis cultures. This finding suggests that further investigations of tafenoquine against dormant mycobacteria are worth pursuing. Moreover, different concentrations of tafenoquine ranging from 1.25 to 80 μM displayed different effects against M. tuberculosis, from moderate (reduction of a 1.8 log CFU/mL) to potent bactericidal (reduction of a 4.2 log CFU/mL) activities. Tafenoquine may represent a hit for further drug optimization and for future clinical development as a new anti-mycobacterial agent, especially in cases of resistant and/or dormant forms of tuberculosis.
Collapse
Affiliation(s)
- Maria Gabriella S Sidrônio
- Programa de Pós-Graduação em Biotecnologia, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil; Laboratório de Biotecnologia Celular e Molecular, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil
| | - Ana Paula O T Castelo Branco
- Laboratório de Biotecnologia Celular e Molecular, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil
| | - Bruno L Abbadi
- Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Brazil; Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil
| | - Fernanda Macchi
- Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Brazil; Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil; Programa de Pós-Graduação em Biologia Celular e Molecular, PUCRS, Porto Alegre, Brazil
| | - Maiele D Silveira
- Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Brazil; Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil
| | - Graziela de A Lock
- Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - Teresa Dalla Costa
- Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - Demétrius M de Araújo
- Programa de Pós-Graduação em Biotecnologia, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil; Laboratório de Biotecnologia Celular e Molecular, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil; Programa de Pós-Graduação em Biotecnologia (Renorbio), Universidade Federal da Paraíba, João Pessoa, Brazil
| | - Samuel Cibulski
- Laboratório de Biotecnologia Celular e Molecular, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil; Programa de Pós-Graduação em Biotecnologia (Renorbio), Universidade Federal da Paraíba, João Pessoa, Brazil
| | - Cristiano V Bizarro
- Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Brazil; Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil; Programa de Pós-Graduação em Biologia Celular e Molecular, PUCRS, Porto Alegre, Brazil
| | - Pablo Machado
- Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Brazil; Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil; Programa de Pós-Graduação em Biologia Celular e Molecular, PUCRS, Porto Alegre, Brazil
| | - Luiz Augusto Basso
- Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Brazil; Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil; Programa de Pós-Graduação em Biologia Celular e Molecular, PUCRS, Porto Alegre, Brazil
| | - Valnês S Rodrigues-Junior
- Programa de Pós-Graduação em Biotecnologia, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil; Laboratório de Biotecnologia Celular e Molecular, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil; Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Brazil.
| |
Collapse
|
2
|
K Hurtado F, Laureano JV, de A Lock G, Derendorf H, Dalla Costa T. Enhanced penetration of moxifloxacin into rat prostate tissue evidenced by microdialysis. Int J Antimicrob Agents 2014; 44:327-33. [PMID: 25218157 DOI: 10.1016/j.ijantimicag.2014.06.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Revised: 06/03/2014] [Accepted: 06/15/2014] [Indexed: 11/18/2022]
Abstract
Moxifloxacin is reported to have increased distribution into the prostate compared with older fluoroquinolones such as norfloxacin and ciprofloxacin, being able to reach tissue-to-plasma concentration ratios greater than unity. However, most of these studies use tissue homogenates derived from biopsy samples, which can lead to overestimation of free concentrations as fluoroquinolones tend to accumulate in the intracellular space. The aim of this study was to investigate moxifloxacin pharmacokinetics in rat prostate interstitial fluid by microdialysis. Tissue pharmacokinetics was assessed by implanting a small microdialysis catheter in the prostate gland. Blood samples were simultaneously collected for assessing plasma pharmacokinetics. Analysis of plasma (N=154) and microdialysis (N=344) concentrations after a single intravenous dose of 6 or 12mg/kg moxifloxacin was conducted in the non-linear mixed-effect modelling software NONMEM v.6 as well by a non-compartmental approach. Moxifloxacin showed a significant tissue distribution in the prostate (AUCprostate,ISF/fu·AUCplasma=1.24±0.37), 59% higher than the value obtained for levofloxacin in a previous study. A three-compartment model with non-linear kinetics could adequately describe moxifloxacin pharmacokinetics in terms of curve fitting and precision in parameter estimation. The developed pharmacokinetic model indicates that passive diffusion and active transport are the mechanisms involved in moxifloxacin distribution to the prostate. These findings suggest that moxifloxacin could be a better alternative to levofloxacin for the treatment of chronic bacterial prostatitis owing to its enhanced tissue penetration and higher AUCtissue/MIC ratios, even though it is not yet approved by the US FDA for this indication.
Collapse
Affiliation(s)
- Felipe K Hurtado
- Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul, Av. Ipiranga 2752, 90610-000 Porto Alegre, RS, Brazil
| | - João Victor Laureano
- Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul, Av. Ipiranga 2752, 90610-000 Porto Alegre, RS, Brazil
| | - Graziela de A Lock
- Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul, Av. Ipiranga 2752, 90610-000 Porto Alegre, RS, Brazil
| | - Hartmut Derendorf
- Department of Pharmaceutics, College of Pharmacy, University of Florida, 1600 SW Archer Road, P.O. Box 100494, Gainesville, FL 32610, USA
| | - Teresa Dalla Costa
- Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul, Av. Ipiranga 2752, 90610-000 Porto Alegre, RS, Brazil.
| |
Collapse
|